Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Medexus Pharmaceuticals Inc. (V:MDP)

Business Focus: Pharmaceuticals (NEC)

Apr 22, 2022 08:30 am ET
Medexus Pharmaceuticals Announces Resubmission of Treosulfan NDA
Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) and medac, a strategic partner of Medexus, are pleased to announce that medac has resubmitted its New Drug Application for Treosulfan (NDA) with the U.S. Food and Drug Administration...
Apr 19, 2022 04:20 pm ET
Medexus to Present at the Bloom Burton & Co. Healthcare Investor Conference
Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) will be presenting at the Bloom Burton & Co. Healthcare Investor Conference from May 2 to 3, 2022. The conference brings together U.S., Canadian, and international investors interested in...
Mar 09, 2022 08:00 am ET
Medexus to Participate in the 34th Annual Roth Conference
Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that it will be participating in the 34th Annual Roth Conference from March 13 to 15, 2022. Event: 34th Annual Roth Conference Date: March...
Mar 01, 2022 07:15 am ET
Medexus Pharmaceuticals Announces Deal for Gleolan in the United States
Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that its U.S. subsidiary, Medexus Pharma (Medexus US), has acquired the exclusive right to commercialize Gleolan in the United States from NX Development Corp....
Feb 14, 2022 08:00 am ET
Medexus Pharmaceuticals Announces Normal Course Issuer Bid, or NCIB, for Convertible Debentures
Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the Toronto Stock Exchange (TSX) has accepted Medexus’s notice of intention to make a normal course issuer bid (NCIB). Under the NCIB, Medexus may purchase for...
Feb 09, 2022 06:30 pm ET
Medexus Pharmaceuticals Generated $21.3M in Fiscal 2022 Third Quarter Revenues and Achieved $1.9M Positive EBITDA for the Three Months Ended December 31, 2021
Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) today announced its financial results and provided a business update for the three-month period ended December 31, 2021. All dollar amounts below are in United...
Feb 01, 2022 04:15 pm ET
Medexus to Present at The MicroCap Rodeo’s 2nd Annual Winter Wonderland Best Ideas Investor Conference
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that it will be presenting at The MicroCap Rodeo’s 2nd Annual Winter Wonderland Best Ideas Investor Conference being held virtually from Feb...
Jan 31, 2022 08:00 am ET
Medexus Schedules Third Quarter Fiscal 2022 Conference Call
Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Thursday, February 10th, 2022, to discuss the Company’s financial results for the...
Jan 28, 2022 10:07 am ET
36 of the Best Ideas Companies to Present at the 2nd Annual Winter Wonderland Virtual Investor Conference on February 8th - 11th, 2022
RALEIGH, NC / ACCESSWIRE / January 28, 2022 / The Winter Wonderland Best Ideas Virtual Investor Conference will take place on February 8th - 11th, 2022, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience.
Jan 07, 2022 09:00 am ET
Medexus to Present at the H.C. Wainwright BioConnect 2022 Conference
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that Ken d’Entremont, Chief Executive Officer of Medexus, and Marcel Konrad, Chief Financial Officer of Medexus, will be presenting at the H.C....
Dec 07, 2021 04:30 pm ET
Sidoti December Micro Cap Virtual Conference
Presentation Times Released for 75+ Presenting Companies
Dec 02, 2021 04:15 pm ET
Medexus to Participate in Two Upcoming Virtual Investor Conferences
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that Ken d’Entremont, Chief Executive Officer of Medexus, and Marcel Konrad, Chief Financial Officer of Medexus, will be participating in two...
Dec 02, 2021 08:08 am ET
Medexus Pharmaceuticals Announces Clear Path to FDA Decision Following medac’s Type A Meeting with FDA on Treosulfan
Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) and medac GmbH (“medac”) announced that medac clarified with FDA details with regard to the projected NDA resubmission of treosulfan, an alkylating agent licensed...
Nov 10, 2021 05:00 pm ET
Medexus Pharmaceuticals Reports Financial and Operational Results for the Three- and Six-Month Periods Ending September 30, 2021
Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) today announced its financial results and provided a business update for the three-month period ended September 30, 2021. All dollar amounts below are in United...
Nov 10, 2021 08:30 am ET
Medexus to Present at the Q4 Investor Summit on November 17th
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that management will present at the Q4 Investor Summit, hosted by the Investor Summit Group, being held virtually on November 16-17, 2021. Ken...
Nov 08, 2021 08:30 am ET
Medexus Pharmaceuticals Announces Appointment of Internal Counsel
Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) today announced that it has appointed Ian C Wildgoose Brown as the Company’s general counsel and corporate secretary. In this role, Mr. Wildgoose Brown will work...
Nov 04, 2021 08:30 am ET
Medexus Schedules Second Quarter Fiscal 2022 Conference Call
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Thursday, November 11, 2021 to discuss the Company’s financial results for the...
Nov 01, 2021 09:27 am ET
Medexus Pharmaceuticals Announces Type A Meeting with FDA Granted for Treosulfan
Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) and medac GmbH (“medac”) today announced that the U.S. Food and Drug Administration (“FDA”) has granted a Type A meeting to medac for treosulfan, a bifunctional...
Oct 26, 2021 08:30 am ET
Medexus to Present at the Benzinga Global Small Cap Conference on October 28, 2021
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that Ken d’Entremont, Chief Executive Officer of Medexus, and Marcel Konrad, Chief Financial Officer of Medexus, are presenting at the Benzinga...
Sep 21, 2021 06:09 pm ET
Medexus Announces Expanded Availability of Trecondyv® (treosulfan) in Canada
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) announced today that it has initiated its first commercial shipment of Trecondyv® (treosulfan) in Canada, following the June 28th, 2021 Notice of Compliance by...
Sep 16, 2021 04:30 pm ET
Medexus Holds Annual and Special Meeting of Shareholders and Announces Election of Board of Directors
Medexus Pharmaceuticals Inc. (the “Company”) (TSX: MDP) (OTCQX: MEDXF) today held its annual and special meeting of shareholders virtually. At the meeting, all of the nominees listed in the Company’s management information circular dated August 6,...
Sep 02, 2021 08:30 am ET
Medexus Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) today announced that Ken d’Entremont, Chief Executive Officer of Medexus, and Marcel Konrad, Chief Financial Officer of Medexus, will be presenting at the H.C....
Aug 16, 2021 05:30 pm ET
Medexus Pharmaceuticals Reports Financial and Operational Results for First Quarter Fiscal 2022
Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) today announced its financial results and provided a business update for the three-month period ended June 30, 2021. All dollar amounts below are in United States...
Aug 12, 2021 07:30 am ET
Medexus Completes Enrollment in Phase 4 Clinical Trial of IXINITY® Targeting Label Expansion for Pediatric Hemophilia B Patients
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that is has completed enrollment in its Phase 4 Clinical Trial of IXINITY®, targeting label expansion for pediatric hemophilia B patients. The...
Aug 10, 2021 08:30 am ET
Medexus Schedules First Quarter Fiscal 2022 Conference Call
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Tuesday, August 17, 2021 to discuss the Company’s financial results for the...
Aug 09, 2021 04:15 pm ET
Medexus to Present at Canaccord Genuity’s 41st Annual Growth Conference
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) announced today that it will be presenting at the Canaccord Genuity 41st Annual Growth Conference being held virtually from August 10th to 12th, 2021. Canaccord...
Aug 04, 2021 10:58 am ET
Medexus Schedules Webinar to Discuss FDA Complete Response Letter for Treosulfan
Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) today announced that it has scheduled a webinar on Thursday, August 5, 2021 at 10:00 a.m. Eastern Time to discuss the Complete Response Letter (CRL) that the...
Aug 03, 2021 07:45 am ET
Complete Response Letter Received from FDA for Treosulfan
Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) and medac GmbH (“medac”) announced today that medac, Medexus’ licensor for treosulfan, has received a Complete Response Letter (CRL) from the Food and Drug...
Jul 19, 2021 07:40 am ET
Medexus Appoints New Chief Financial Officer
Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce the appointment of Marcel Konrad as Chief Financial Officer of the Company, effective immediately. Mr. Konrad succeeds Roland Boivin, who is...
Jul 12, 2021 09:29 am ET
Medexus Pharmaceuticals and medac GmbH enter into Licensing Agreement for First-in-Class Conditioning Agent, Treosulfan, in Canada
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that it has entered into a licensing agreement, formalizing its relationship with medac GmbH (“medac”) to commercialize treosulfan, a bifunctional...
Jul 07, 2021 11:00 am ET
Medexus Virtually Opens The Market
TORONTO, July 7, 2021 /CNW/ - Ken D'Entremont, Chief Executive Officer, Medexus Pharmaceuticals Inc., ("Medexus" or the "Company") (TSX: MDP), and his team joined Daniel Lubienietzky, Manager, Life Sciences, TMX Group, to celebrate the Company's new listing on Toronto Stock Exchange and open the market.
Jun 28, 2021 04:30 pm ET
Medexus Receives Notice of Compliance to Commercialize Treosulfan in Canada
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that it has received a Notice of Compliance (“NOC”) from Health Canada to commercialize treosulfan, developed by medac GmbH, in Canada, following...
Jun 16, 2021 05:00 pm ET
Medexus Revenue Increases 43.5% to a Record US$79.7 Million for Fiscal 2021
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced its financial and operating results for the fourth quarter and fiscal year ended March 31, 2021. As greater than 75% of the Company’s revenue is now...
Jun 15, 2021 04:05 pm ET
Medexus Announces Graduation to the Toronto Stock Exchange
Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSXV:MDP) (OTCQX: MEDXF) announced today that it has received final approval for listing of the Company’s common shares (the “Common Shares”) on the Toronto Stock Exchange (the “TSX”). In...
Jun 14, 2021 08:30 am ET
Medexus to Present at Raymond James Human Health Innovation Conference
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it will be presenting at the Raymond James Human Health Innovation Conference on June 21st, 2021. Ken d’Entremont, Chief...
Jun 11, 2021 08:30 am ET
Medexus Schedules Fiscal Year 2021 Conference Call
, June 11, 2021 - Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Thursday, June 17, 2021 to discuss the...
Jun 10, 2021 08:30 am ET
Medexus Strengthens Medical Affairs Team in Preparation for Planned Treosulfan Launch
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) today announced that it has expanded its medical affairs team in preparation for the planned launch of treosulfan, a bifunctional alkylating...
Jun 09, 2021 08:30 am ET
Medexus Announces Availability of Triamcinolone Hexacetonide in the United States
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it is initiating immediate availability of Triamcinolone Hexacetonide Injectable Suspension, USP (20 mg/ml) (TH) in the...
Jun 01, 2021 08:30 am ET
Medexus to Present at The LD Micro Virtual Invitational XI on June 8th
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: MEDXF), today announced that management will present at the LD Micro Invitational XI investor conference taking place virtually June 8-10, 2021. Ken d’Entremont, Chief...
May 27, 2021 05:00 pm ET
Medexus Announces Amendments to its Credit Agreements
Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSXV:MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it has entered into certain amendments (collectively, the “Amendments”) to its existing credit agreements with a syndicate of...
May 18, 2021 05:30 pm ET
May 12, 2021 08:30 am ET
Medexus to Present at the Sidoti & Company Virtual Microcap Conference on May 19th
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it will be presenting at the Sidoti & Company Virtual Microcap Conference being held on May 19th - May 20th, 2021. Ken...
Apr 12, 2021 08:30 am ET
Medexus Announces Conference Participation for April 2021
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731), today announced that Ken d’Entremont, CEO, and Roland Boivin, CFO, will be participating in the Bloom Burton & Co. Healthcare Investor...
Mar 31, 2021 05:05 pm ET
Medexus Reports All Medexus Non-Executive Directors Choose RSUs in Lieu of Cash Fees
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) is pleased to report that the Company’s non-executive directors were permitted to make a one-time, irrevocable election, to receive restricted...
Mar 08, 2021 08:30 am ET
Medexus to Participate in the 33rd Annual ROTH Conference on March 15-17, 2021
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that Ken d’Entremont, Chief Executive Officer, and Roland Boivin, Chief Financial Officer of Medexus, will be conducting 1x1...
Mar 01, 2021 05:00 pm ET
Medexus Achieves Record Revenue of $31.5 Million for the Third Quarter Fiscal 2021
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) today announced its financial and operating results for the three and nine months ended December 31, 2020. All dollar amounts below are in...
Feb 25, 2021 09:00 am ET
Medexus Announces Expanded Availability of Gleolan® in Canada
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it has initiated the commercial launch of Gleolan® in Canada, which had previously only been distributed under the Health...
Feb 24, 2021 09:00 am ET
Medexus Schedules Third Quarter Fiscal 2021 Conference Call
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Tuesday, March 2, 2021 to discuss the Company’s financial...
Feb 23, 2021 08:51 am ET
Medexus Announces Closing of $32.5 Million Public Offering, Including Exercise in Full of Over-Allotment Option
Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSXV:MDP) (Frankfurt: P731) announced today that it has closed its previously announced bought deal public offering of 4,581,689 units (the “Units”) at a price of $7.10 per Unit for total...
Feb 16, 2021 04:43 pm ET
Medexus to Present at the Winter Wonderland Conference- Best Ideas from the Buy-Side
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it will be presenting at the Winter Wonderland Conference, hosted by The MicroCap Rodeo, being held virtually on February...
Feb 03, 2021 10:09 am ET
Medexus Announces Upsize to Previously Announced Bought Deal Public Offering
Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSXV:MDP) (Frankfurt: P731) is pleased to announce that, due to strong demand, it has agreed with Raymond James Ltd. and Stifel GMP, as co-lead underwriters and joint bookrunners, on behalf...
Feb 03, 2021 09:44 am ET
IIROC Trading Resumption - MDP
VANCOUVER, BC, Feb. 3, 2021 /CNW/ - Trading resumes in:
Feb 02, 2021 03:03 pm ET
Medexus Announces $20 Million Bought Deal Public Offering of Units
Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSXV:MDP) (Frankfurt: P731) is pleased to announce that it has entered into an agreement with Raymond James Ltd. and Stifel GMP as co-lead underwriters and joint bookrunners, on behalf of a...
Feb 02, 2021 02:21 pm ET
Medexus Pharmaceuticals and medac GmbH enter into a License Agreement for First-in-Class Conditioning Agent for Hematopoietic Stem Cell Transplantation, Treosulfan, in the United States
Medexus Pharmaceuticals Inc. (“Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) is pleased to announce that it and its wholly-owned United States-based subsidiary, Medexus Pharma, Inc. (“Medexus Pharma” and together with Medexus, the...
Feb 02, 2021 02:04 pm ET
IIROC Trading Resumption - MDP
VANCOUVER, BC, Feb. 2, 2021 /CNW/ - Trading resumes in:
Feb 02, 2021 01:59 pm ET
IIROC Trading Halt - MDP
VANCOUVER, BC, Feb. 2, 2021 /CNW/ - The following issues have been halted by IIROC:
Feb 02, 2021 01:16 pm ET
IIROC Trading Halt - MDP
VANCOUVER, BC, Feb. 2, 2021 /CNW/ - The following issues have been halted by IIROC:
Jan 25, 2021 08:30 am ET
Medexus Announces Renewal and Expansion of Canadian Distribution Agreement for NYDA®
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it has renewed and expanded its distribution agreement for NYDA®, a market leading treatment for head lice, through...
Jan 21, 2021 08:30 am ET
Medexus Submits Application to List on the Nasdaq
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it has submitted its application to list on The Nasdaq Capital Market® (the “Nasdaq”). Ken d’Entremont, Chief Executive...
Jan 06, 2021 05:00 pm ET
Medexus Engages Independent Trading Group for Market Making Services
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it has engaged Independent Trading Group (ITG), Inc. (“ITG”) to provide market-making services to the Company in accordance...
Dec 29, 2020 09:30 am ET
TMX Group, Medexus, C-Suite at The Open
TORONTO, Dec. 29, 2020 /CNW/ - Ken d'Entremont, CEO, Medexus Pharmaceuticals Inc. (TSXV: MDP), shares his company's story in an interview with TMX Group.
Dec 21, 2020 05:30 pm ET
Medexus Announces Annual Equity Incentive Grants to Non-Executive Directors
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that the board of directors of the Company (the “Board”) has formally granted (the “Annual Grants”) restricted share units...
Dec 21, 2020 08:52 am ET
Dec 21, 2020 08:52 am ET
Dec 18, 2020 08:30 am ET
Medexus Enters into Exclusive License to Register and Commercialize Triamcinolone Hexacetonide (TH) in the United States with Ethypharm
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) is pleased to announce it has entered into an exclusive license agreement with Ethypharm (“Ethypharm”) to register and commercialize...
Dec 08, 2020 08:30 am ET
Medexus to Present at The 13th Annual LD Micro Main Event Conference on December 15th
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: MEDXF), today announced that it will be presenting at the 13th Annual LD Micro Main Event investor conference on Tuesday, December 15th at 8:00 a.m. PST / 11:00 a.m. EST....
Dec 07, 2020 07:35 am ET
Innovation Investor Conference Presentations Now Available for On-Demand Viewing
Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations
Dec 07, 2020 07:35 am ET
Innovation Investor Conference Presentations Now Available for On-Demand Viewing
NEW YORK, Dec. 7, 2020 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the Innovation Virtual lnvestor Conference are now available for on-demand viewing.
Dec 02, 2020 07:30 am ET
Medexus to Webcast Live at VirtualInvestorConferences.com December 3rd
TORONTO and CHICAGO and MONTREAL, Dec. 2, 2020 /PRNewswire/ -- Medexus Pharmaceuticals Inc. (the "Company" or "Medexus") (TSXV: MDP, OTCQX: MEDXF), today announced that Ken d'Entremont, Chief Executive Officer and Roland Boivin, Chief Financial Officer of Medexus, will present live at VirtualInvestorConferences.com on December 3rd.  
Nov 30, 2020 08:38 am ET
Live Innovation Investor Conference & Webinar: Public Company Presentations December 3rd
Company executives will share vision and answer audience questions at VirtualInvestorConferences.com
Nov 30, 2020 08:28 am ET
Live Innovation Investor Conference & Webinar: Public Company Presentations December 3rd
NEW YORK, Nov. 30, 2020 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Innovation lnvestor Conference. Individual investors, institutional investors, advisors and analysts are invited to attend. The program opens at 8:45 AM ET on Thursday, December 3rd with the first live webcast at 9:00 AM ET.
Nov 16, 2020 05:15 pm ET
Medexus Pharmaceuticals Reports Operating and Financial Results for the Three- and Six-Month Periods Ending September 30, 2020
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced its financial and operating results for the three and six months ended September 30, 2020.  All dollar amounts below are in Canadian...
Nov 16, 2020 08:00 am ET
Medexus Reaches 50% Enrollment in IXINITY® Phase 4 Clinical Trial Targeting Label Expansion for Pediatric Hemophilia B Patients
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: MEDXF) today announced it has reached the 50% enrollment target in its Phase 4 clinical trial investigating IXINITY® as a prophylactic treatment for pediatric patients...
Nov 09, 2020 08:30 am ET
Medexus Pharmaceuticals Schedules Second Quarter Fiscal 2021 Conference Call
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Tuesday, November 17, 2020 to discuss the Company’s financial...
Oct 30, 2020 12:30 pm ET
Medexus Announces Engagement of Westmount Capital and Equity Incentive Grants to Insiders
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it has entered into a consulting agreement (the “Consulting Agreement”) with Westmount Capital (“Westmount”) to provide...
Oct 08, 2020 03:30 pm ET
The MicroCap Rodeo Best Ideas Bowl 2020; October 13-16, 2020
NEW YORK, NY / ACCESSWIRE / October 8, 2020 / The MicroCap Rodeo continues this year with its first virtual event set for October 13-16, 2020. This year' "Best Ideas" conference focuses solely on 25 public companies recommended by institutional investors and qualified individual investors. The event will feature 2 days of company presentations followed by 2 days of pre-scheduled 1-1's.
Sep 25, 2020 08:30 am ET
Medexus Appoints Michael Pine as Senior Vice President of Business Development and Strategy
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: MEDXF), today announced the appointment of Michael Pine as Senior Vice President of Business Development and Strategy, effective September 21, 2020. Mr. Pine’s...
Sep 18, 2020 10:38 am ET
Medexus Engages Adelaide Capital for Investor Relations Services and Reports Annual Meeting Results
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) is pleased to announce that it has entered into a consulting agreement (the “Consulting Agreement”) with Adelaide Capital (“Adelaide”) to provide investor...
Sep 10, 2020 09:20 am ET
Medexus Reports Health Canada Approval of Gleolan® (5-ALA) for Use in Guided Surgical Resection of High-Grade Gliomas
Medexus Pharmaceuticals Inc.  (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: MEDXF) today announces that on September 9, 2020, it received a Notice of Compliance from Health Canada granting approval for the marketing of Gleolan® in Canada....
Aug 31, 2020 05:00 pm ET
LD Micro - 360 Companies - Set to Present this Week
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Aug 25, 2020 09:30 am ET
Medexus to Present at The LD 500 Virtual Conference on September 1st
MONTREAL, QC / ACCESSWIRE / August 25, 2020 / Medexus Pharmaceuticals Inc. (the "Company" or "Medexus") (TSXV:MDP) (OTCQX:MEDXF) today announced that it will be presenting at the LD 500 Investor conference being held virtually on September 1-4, 2020.
Aug 24, 2020 07:57 pm ET
Medexus Announces Move to a Virtual Meeting for 2020 AGM and Equity Incentive Grants
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: PDDPF) today announced that due to public health restrictions related to the COVID-19 pandemic, its annual general meeting (the “Meeting”) will be held virtually by live...
Aug 24, 2020 08:00 am ET
Medexus Reports Triamcinolone Hexacetonide Injectable Suspension Approved for Inclusion on Quebec’s RAMQ List of Medications (Basic Plan and Institutions)
Medexus Pharmaceuticals Inc.  (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: MEDXF) is pleased to announce that Triamcinolone Hexacetonide Injectable Suspension 20 mg/mL (TH) has been approved for inclusion as a general benefit (open listing) on...
Aug 21, 2020 11:36 am ET
Medexus Announces New U.S. Ticker “MEDXF” on the OTCQX
Medexus Pharmaceuticals Inc.  (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: MEDXF; PDDPF) today announces that it has begun trading on the OTCQX® Best Market under the new ticker “MEDXF,” effective August 20, 2020. Medexus Pharmaceuticals Inc was...
Aug 11, 2020 05:19 pm ET
Medexus Pharmaceuticals Reports Record Revenue of $27.5 Million and $5.0 Million of Adjusted EBITDA* for the First Quarter of Fiscal 2021
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: PDDPF) today provided a business update and announced its financial and operating results for the three-month period ended June 30, 2020.  All dollar amounts below are in...
Aug 11, 2020 08:30 am ET
Medexus Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth Conference on August 12th  
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: PDDPF) today announced that it will be presenting at the Canaccord Genuity 40th Annual Growth Conference being held virtually on August 11-13, 2020. Ken d’Entremont,...
Aug 05, 2020 09:00 am ET
LD Micro - Announces Preliminary List of Presenters for the LD 500
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Aug 05, 2020 08:30 am ET
Medexus Pharmaceuticals Schedules First Quarter Fiscal 2021 Conference Call
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: PDDPF) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Wednesday, August 12, 2020 to discuss the Company’s financial results for the...
Aug 04, 2020 04:30 pm ET
OTC Markets Group Welcomes Medexus Pharmaceuticals Inc. to OTCQX
NEW YORK, Aug. 4, 2020 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Medexus Pharmaceuticals Inc. (TSX-V: MDP;  OTCQX: PDDPF), a commercial-stage specialty pharmaceutical company, has qualified to trade on the OTCQX® Best Market. Medexus Pharmaceuticals Inc upgraded to OTCQX from the OTCQB® Venture Market.
Jul 09, 2020 08:30 am ET
Medexus Reports Triamcinolone Hexacetonide Injectable Suspension Approved for Inclusion on Federal/Provincial/Territorial Public Drug Plan Formularies
Medexus Pharmaceuticals Inc.  (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) is pleased to announce that Triamcinolone Hexacetonide Injectable Suspension 20 mg/mL (TH) has been approved for inclusion on the Alberta Drug Benefit List (ADBL),...
Jun 22, 2020 05:15 pm ET
Medexus Pharmaceuticals Reports Record Revenue of $25.6 Million and $4.2 Million of Adjusted EBITDA* for the Fourth Quarter of Fiscal 2020
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today provided a business update and announced its financial and operating results for the fourth quarter and fiscal year ended March 31, 2020.  All dollar amounts...
Jun 17, 2020 09:15 am ET
Medexus Pharmaceuticals Schedules Fiscal Year 2020 Conference Call
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Tuesday, June 23, 2020 to discuss the Company’s financial results for the fiscal...
Jun 03, 2020 09:00 am ET
Medexus to Present at the Virtual Summer Summit on June 10th
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX-V: MDP, OTCQB: PDDPF) today announced that it will be presenting at the 2020 Virtual Summer Summit being held on June 9th-12th. Ken d’Entremont, CEO and Roland Boivin, CFO are...
Jun 03, 2020 09:00 am ET
47 Public Companies to present at the Summer Virtual Investor Summit on June 9th-12th
NEW YORK, NY / ACCESSWIRE / June 3, 2020 / The Virtual Summer Summit will take place on June 9th-12th, connecting 47 presenting small and microcap companies with distinguished investors from around the globe. A full list of issuers are listed below along with webcasting links to view presentations.
May 22, 2020 08:51 am ET
Medexus Provides an Update on the IXINITY® Acquisition and its Overall Business in the COVID-19 Environment
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX-V: MDP, OTCQB: PDDPF) today provided an update on its business in light of the recent transformative acquisition of the commercial hematology asset, IXINITY®, the resulting...
May 07, 2020 05:00 pm ET
Medexus Announces US$20 Million Asset-Based Credit Facility and Repays US$10 Million of its Term Loan
Medexus Pharmaceuticals Inc.  (the “Company” or “Medexus”) (TSX-V: MDP, OTCQB: PDDPF) today announced that the Company has entered into a definitive credit agreement with a syndicate of lenders agented by MidCap Financial Trust (“MidCap Financial”)...
Apr 08, 2020 08:30 am ET
Medexus Reports Triamcinolone Hexacetonide Injectable Suspension Approved for Public Reimbursement in Canada
Medexus Pharmaceuticals Inc.  (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) is pleased to announce that the pan-Canadian Pharmaceutical Alliance (pCPA) price negotiations for Triamcinolone Hexacetonide Injectable Suspension 20mg/mL (TH) in...
Mar 23, 2020 01:24 pm ET
Medexus to Present at the Spring Investor Summit on March 25th
Medexus Pharmaceuticals Inc.  (the “Company” or “Medexus”) (TSX-V: MDP, OTCQB: PDDPF) today announced that it will be presenting at the 2020 Spring Investor Summit being held on March 25th-26th, featuring over 500 registered executives and...
Mar 23, 2020 08:30 am ET
Medexus Provides a Business Update and Outlines Response to COVID-19 Pandemic
Medexus Pharmaceuticals Inc.  (the “Company” or “Medexus”) (TSX-V: MDP, OTCQB: PDDPF) today provided an update to its shareholders reaffirming the strength of its business and outlining the measures it has taken in light of the COVID-19 healthcare...
Feb 28, 2020 08:59 am ET
Medexus Expands its US Product Portfolio by Acquiring the Hematology Asset IXINITY®
Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSXV: MDP, OTCQB: PDDPF) today announced that the Company, through its US-based subsidiary, acquired Aptevo BioTherapeutics LLC, a Delaware limited liability company owning the worldwide...
Feb 18, 2020 06:52 pm ET
Medexus Pharmaceuticals Reports Revenue of $16.2 Million for the Third Quarter of Fiscal 2020
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today provided a business update and announced its financial and operating results for the three- and nine- month periods ended December 31, 2019.  All dollar...
Feb 12, 2020 08:30 am ET
Medexus Pharmaceuticals Schedules Third Quarter Fiscal 2020 Conference Call
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Wednesday, February 19, 2020 to discuss the Company’s financial results for the...
Nov 29, 2019 05:00 pm ET
Medexus Pharmaceuticals Reports Operating and Financial Results for the Second Quarter of Fiscal 2020
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today provided a business update and announced its financial and operating results for the three- and six-month periods ended September 30, 2019.  All dollar...
Nov 25, 2019 09:22 am ET
Medexus Pharmaceuticals Schedules Second Quarter Fiscal 2020 Conference Call
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Monday, December 2, 2019 to discuss the Company’s financial results for the...
Nov 19, 2019 08:30 am ET
Medexus Granted Priority Review Status for Gliolan® by Health Canada
Medexus Pharmaceuticals Inc.  (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today announced that Health Canada has granted priority review status for the New Drug Submission (NDS) for Gliolan® (5-aminolevulinic acid hydrochloride)....
Oct 22, 2019 09:00 am ET
Medexus Pharmaceuticals to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference
Medexus Pharmaceuticals Inc.  (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today announced that it will be presenting at the Dawson James Securities 5th Annual Small Cap Growth Conference being held on October 28-29, 2019 at the Wyndham...
Oct 15, 2019 11:43 am ET
Medexus Announces Changes to Senior Management
Medexus Pharmaceuticals Inc. (the “Company”) (TSXV: MDP, OTCQB: PDDPF) today announced changes to the Company’s senior management team. Effective immediately, Mr. Sylvain Chrétien will no longer serve as the Company’s President, Canadian...
Sep 19, 2019 08:30 am ET
Medexus Reports Annual Meeting Results
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) announces voting results from its Annual Meeting of Shareholders held on September 18, 2019 in Toronto, Ontario (the “Meeting”). A total of 5,228,034 Common...
Sep 12, 2019 08:30 am ET
Medexus Reports Health Quality Ontario Recommends Gliolan® for Public Reimbursement
Medexus Pharmaceuticals Inc.  (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today announced that Health Quality Ontario, under the guidance of the Ontario Health Technology Advisory Committee, has recommended public  funding of Gliolan®...
Aug 22, 2019 04:01 pm ET
Medexus Pharmaceuticals Reports Operating and Financial Results for the First Quarter of Fiscal 2020
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today provided a business update and announced its financial and operating results for the fiscal quarter ended June 30, 2019.  All dollar amounts below are in...
Aug 16, 2019 11:00 am ET
Medexus Pharmaceuticals Schedules First Quarter Fiscal 2020 Conference Call
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today announced that it plans to host a conference call at 4:30 PM Eastern Time on Thursday, August 22, 2019 to discuss the Company’s financial results for the...
Aug 15, 2019 04:05 pm ET
Medexus Announces DTC Eligibility of its Common Shares in the United States
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) is pleased to announce that the Company's common shares traded in the United States, under the symbol PDDPF, are Depository Trust Company (“DTC”) eligible. DTC is...
Jul 08, 2019 04:05 pm ET
Medexus Pharmaceuticals Announces Operating and Financial Results for Fourth Quarter and Full Fiscal Year Ended March 31, 2019
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today provided a business update and announced its financial and operating results for the fourth quarter and fiscal year ended March 31, 2019.  All dollar amounts...
Jun 28, 2019 08:00 am ET
Medexus Pharmaceuticals Schedules Fourth Quarter and Fiscal 2019 Conference Call
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today announced that it plans to host a conference call at 4:30 PM Eastern Time on Monday, July 8, 2019 to discuss the Company’s financial results for the fourth...
Jun 25, 2019 08:00 am ET
Medexus Appoints Accomplished Global Pharmaceutical Industry Executive Adele M. Gulfo to its Board of Directors
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF), a leading specialty pharmaceutical company with a strong North American commercial platform, announces that Adele M. Gulfo has joined the Company's Board of...
May 14, 2019 08:00 am ET
Medexus Pharmaceuticals Announces Normal Course Issuer Bid
Medexus Pharmaceuticals Inc.  (the “Company”) (TSXV: MDP, OTCQB: PDDPF) announced today it has submitted to the TSX Venture Exchange (the “Exchange”) a notice of its intention to make a normal course issuer bid (the “Bid”).  Provided the Company...
May 07, 2019 12:43 pm ET
Medexus Pharmaceuticals Launches New Metoject® Subcutaneous 15mg Dosage for the Treatment of Rheumatoid Arthritis, Psoriasis and Psoriatic Arthritis in Canada
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF), today announced the launch of a new Metoject® Subcutaneous 15mg dose in Canada. Metoject Subcutaneous is a pre-filled syringe of methotrexate with a pre-attached...
Apr 23, 2019 08:00 am ET
Medexus CEO to Present at Two Upcoming Investor Conferences
Medexus Pharmaceuticals Inc.  (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) announces that Ken d’Entremont, Chief Executive Officer, has been invited to present and meet with investors at two upcoming investor conferences. Medexus is...
Mar 06, 2019 07:50 am ET
Medexus Granted Authorization by Health Canada to Distribute Treosulfan in Canada
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today announced that Health Canada has authorized the Company to distribute Treosulfan, a conditioning agent used prior to stem cell transplantation.  Authorization...
Mar 04, 2019 08:00 am ET
Medexus Enters into Expanded Licensing Agreement for Gliolan® in Canada
Medexus Pharmaceuticals Inc.  (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today announced that it has entered into a licensing agreement with photonamic GmbH & Co. KG (“photonamic”) for the exclusive rights to market and distribute...
Feb 25, 2019 04:05 pm ET
Medexus Pharmaceuticals Announces 512% Increase in Revenue to $14.4 Million for the Third Quarter of Fiscal 2019
Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.) (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today provided a business update and announced its operating and financial results for the fiscal third quarter ended December 31, 2018....
Feb 13, 2019 08:00 am ET
Medexus Pharmaceuticals Schedules Third Quarter Fiscal 2019 Conference Call
Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.) (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today announced that it plans to host a conference call at 4:30 PM Eastern Time on Monday, February 25, 2019 to discuss the Company’s...
Feb 12, 2019 08:00 am ET
Medexus Lists October 2018 Unsecured Convertible Debentures on the TSX Venture Exchange
Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.) (the “Company”) (TSXV: MDP, OTCQB: PDDPF) today announced that the 6.0% unsecured convertible debentures of the Company (the “Debentures”) will commence trading on the TSX Venture Exchange...
Jan 07, 2019 02:35 pm ET
Medexus Files Business Acquisition Report
Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.) (the “Company”) (TSXV: MDP, OTCQB: PDDPF) today announced the filing of the Business Acquisition Report (“BAR”) on SEDAR (www.sedar.com) in relation to the previously announced transaction...